Download PDF
Thromb Haemost 1994; 72(01): 119-124
DOI: 10.1055/s-0038-1648822
Original Article
Schattauer GmbH Stuttgart

Inhibition of Thrombosis by a Selective Fibrinogen Receptor Antagonist without Effect on Bleeding Time

Juerg F Tschopp
1   Telios Pharmaceuticals, San Diego, GA, USA
,
Curt Mazur
1   Telios Pharmaceuticals, San Diego, GA, USA
,
Kenneth Gould
2   The Department of Surgery, Tufts-New England Medical Center, Boston, MA, USA
,
Raymond Connolly
2   The Department of Surgery, Tufts-New England Medical Center, Boston, MA, USA
,
Michael D Pierschbacher
1   Telios Pharmaceuticals, San Diego, GA, USA
3   The Cancer Research Center, La Jolla Cancer Research Foundation La Jolla, CA, USA
› Author Affiliations
Further Information

Publication History

Received 19 August 1993

Accepted after resubmission 01 March 1994

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Membrane glycoprotein αIIbβ3 on platelets plays a pivotal role in hemostasis by mediating RGD-(arginine-glycine-aspartic acid)-dependent platelet adhesion and aggregation. Antagonists of αIIbβ3 ligand binding function, such as antibodies, snake venom peptides, or synthetic RGD-containing peptides can completely inhibit platelet aggregation in vitro and cause significant prolongation of bleeding times when injected into experimental animals. The in vitro and in vivo properties of an αIIbβ3 specific RGD-containing peptide 2G (G(Ten)GHRGDLRCA) were compared to two non-specific RGD-containing peptides IN (G(Pen)GRGDTPCA) and 2H (GRGDSPDG). All three peptides have similar IC50 values in human patelet aggregation (14-22 μM) and ELISA-based μIIbβ3 receptor assays (0.2–0.3 αM) but show different inhibitory activity (IC50 values) in the αv㯂5 (2G = 10 μM; IN = 0.06 μM; 2H = 0.05 μM) and receptor assays (2G = 8.3 μM; IN = 0.06 μM; 2H = 0.04). The αIIbβ3 specific peptide 2G had no effect on monolayers of human saphenous vein endothelial cells while IN and 2H caused many cells to detach and contract. Peptides 2G and IN inhibited ADP-stimulated ex vivo platelet aggregation in dogs in a dose dependent manner. When complete inhibition (>90%) of ex vivo platelet aggregation was achieved with either a 10 mg/kg bolus followed by a 16mg/kg/h infusion of 2G or with a 15 mg/kg bolus and 24 mg/kg/h infusion of IN, peptide IN caused a dose-dependent increase of the template bleeding time, while peptide 2G had no effect, even at doses up to 15 mg/kg bolus followed by 24 mg/kg/h infusion. The in vivo properties of peptides 2G and 2H were also examined in a baboon ex vivo shunt model for their ability to block platelet uptake and fibrinogen deposition on small caliber GORE-TEX® grafts and for their effect on the hemostatic system. Systemic administration of peptide 2G at 10 mg/kg bolus followed by 10 mg/kg/h infusion (or at a 2-fold lower dose) abolished platelet uptake and fibrinogen deposition on the graft surface without affecting the hemostasis and template bleeding time of the animal. By contrast, peptide 2H caused a 3-4-fold increase in bleeding time at a dose of 10 mg/kg. The results suggest that efficacy and the effect of specific aIIbp3antagonists on bleeding time can be separated and that selective aIIbP3 receptor blockade may be an efficient and safe approach to improve the patency and the success rate pf small caliber vascular grafts and to treat unwanted platelet-dependent thromboses. While peptide 2G may represent a unique class of antithrombotic agent, the clinical use of this type of molecule would require a significant enhancement in potency.

 

  • References

  • 1 Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 1985; 82: 8057-8061
    CrossrefPubMedGoogle Scholar
  • 2 Gartner TK, Bennett JS. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J Biol Chem 1985; 26: 1189M
    PubMedGoogle Scholar
  • 3 Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa is a member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986; 231: 1159-1162
    PubMedGoogle Scholar
  • 4 Kieffer N, Phillips DR. Platelet membrane glycoproteins: functions in cellular interactions. Annu Rev Cell Biol 1990; 6: 329-357
    CrossrefPubMedGoogle Scholar
  • 5 Ruoslahti E. Integrins. J Clin Invest 1991; 87: 1-5
    CrossrefPubMedGoogle Scholar
  • 6 Sakariassen KS, Nievelstein PFEM, Coller BS, Sixma J. The role of platelet membrane glycoproteins ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol 1986; 63: 681-691
    CrossrefPubMedGoogle Scholar
  • 7 Glino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson J. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 1988; 77: 678-684
    CrossrefPubMedGoogle Scholar
  • 8 Berger S, Salzman EW. Thromboembolic complications of prosthetic devices. In: Progress in Hemostasis and Thrombosis Spaet TH. (ed.) New York: Grune and Stratton, Inc; 1974. 2 273-309
  • 9 George JN, Nurden AT, Phillips DR. Molecular defects in interactions of platelets with the vessel wall. N Engl J Med 1984; 311: 1084-1098
    CrossrefPubMedGoogle Scholar
  • 10 Fournier DJ, Kabral A, Castaldi PA, Berndt MC. A variant of Glanzman’s thrombastenia characterized by abnormal glycoprotein Ilb/IIIa complex formation. Thromb Haemost 1989; 62: 977-983
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Coller BS, Peerschke El, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombastenic-like state in normal platelets and binds to glycoproteins lib and/or Ilia. J Clin Invest 1983; 72: 325-338
    CrossrefPubMedGoogle Scholar
  • 12 Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokioff MA. Echistatin: a potent platelet aggregation inhibitor from the venom of the viper, echis carinatus. J Biol Chem 1988; 263: 19827-19832
    PubMedGoogle Scholar
  • 13 Dennis MS, Henzel WJ, Pitti RM, Lipari MI, Napier MA, Deisher TA, Bunting S, Lazarus RA. Platelet glycoprotein GPIIb/IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci USA 1989; 87: 2471-2475
    PubMedGoogle Scholar
  • 14 Huang TF, Holt JC, Kirby EP, Niewiarowski S. Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein Ilb/IIIa complex on human platelets. Biochemistry 1989; 28: 661-666
    CrossrefPubMedGoogle Scholar
  • 15 Cadroy Y, Houghton RA, Hanson SR. RGDV peptide selectivity inhibits platelet-dependent thrombus formation in vivo-studies using a baboon model. J Clin Invest 1989; 84: 939-944
    CrossrefPubMedGoogle Scholar
  • 16 Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, Kind LW, Miyano M, Gorczynski RJ, Williams MH, Zupec ME, Tjoeng FS, Adams SP, Feigen LP. Antiplatelet and antithrombotic effects of platelet glycoprotein Ilb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-Me) Y (SC-46749). J Pharm Exp Ther 1991; 256: 876-882
    PubMedGoogle Scholar
  • 17 Barker PL, Bullens S, Bunting S, Burdick DJ, Chan KS, Deisher DT. Cyclic RGD peptide analogues as antiplatelet antithrombotics. J Med Chem 1992; 35: 2040-2048
    CrossrefPubMedGoogle Scholar
  • 18 Gold HK, Coller B, Yasuda T, Saito T, Fallon JT, Guerrero L, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988; 77: 670-677
    CrossrefPubMedGoogle Scholar
  • 19 Lu HR, Gold HK, Wu Z, Yasuda T, Pauwels P, Rapold HJ, Napier M, Bunting S, Collen D. G4120, an Arg-Gly-Asp containing pentapeptide enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs. Thromb Haemost 1992; 67: 686-691
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation 1991; 83: 1038-1047
    CrossrefPubMedGoogle Scholar
  • 21 Cheng S, Craig WS, Mullen D, Tschop JF, Dixon D, Pierschbacher MD. Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin aIIbB3 antagonists. J Med Chem 1994 in press
    PubMedGoogle Scholar
  • 22 Pytela R, Pierschbacher MD, Ruoslahti E. A 125/115kDa cell surface receptor specific for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin. Proc Natl Acad Sci USA 1985; 82: 5766-5770
    CrossrefPubMedGoogle Scholar
  • 23 Pytela R, Pierschbacher MD, Ruoslahti E. Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell 1985; 40: 191-198
    CrossrefPubMedGoogle Scholar
  • 24 Eldrup-Jorgensen J, Mackey WC, Connolly RJ, McCullough JL, Ramberg K, Gavris V, O’Donnell TF, Callow AD. Evaluation of arterial prostheses in a baboon ex vivo shunt: the effect of graft material and flow on platelet deposition. Am J Surgery 1985; 150: 185-190
    CrossrefPubMedGoogle Scholar
  • 25 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-1084
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Pierschbacher MD, Ruoslahti E. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xxx on binding specificity in cell adhesion. J Biol Chem 1987; 262: 17294-17298
    PubMedGoogle Scholar
  • 27 Harker LA, Hanson SR, Kirkman TR. Experimental arterial thromboembolism in baboons. Mechanism, quantitation, and pharmacological prevention. J Clin Invest 1979; 64: 559-569
    CrossrefPubMedGoogle Scholar
  • 28 Mickelson JK, Simpson PJ, Cronin M, Hofmeister JW, Lawell E, Kitzen S, Lucchesi BR. Antiplatelet antibody [7E3F(ab’)2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation 1990; 81: 617-627
    CrossrefPubMedGoogle Scholar
  • 29 Baker WH, Hadcock MM, Littooy FN. Management of polytetraflu-oroethylene graft occlusion. Arch Surg 1980; 115: 508-513
    CrossrefPubMedGoogle Scholar
  • 30 Rutherford RB, Ross R. Platelet factors stimulate fibroblasts and smooth muscle cells quiescent in plasma serum to proliferate. J Cell Biol 1976; 69: 196-203
    CrossrefPubMedGoogle Scholar
  • 31 Connolly RJ, Eldrup-Jorgensen J, Shepard A, Ramberg K, Mackey W, Keough E, McCullough J, Callow AD. The Tufts baboon ex vivo shunt: an animal model for the study of the interaction of blood with prosthetic vascular grafts. Surgical Research 1985; 139: 139-145
    PubMedGoogle Scholar
  • 32 Mehta S. A statistical summary of the results of femoral popliteal bypass surgery. Newark, Delaware: W. L. Gore and associates, Inc; 1980
    Google Scholar
  • 33 Callow AD, Ledig CB, O’Donnell TF, Kelly JJ, Rosenthal D, Corwin S, Hotte C, Kahn PC, Vecchione JJ, Valerie CR. A primate model for the study of the interaction of niIndium labeled platelets with Dacron arterial prostheses. Ann Surg 1980; 191: 362-366
    CrossrefPubMedGoogle Scholar
  • 34 Tschopp JF, Driscoll EM, Mu D-X, Black SC, Pierschbacher MD, Lucchesi BR. Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time. Coronary Artery Disease 1993; 4: 809-817
    CrossrefPubMedGoogle Scholar
  • 35 Cheng S, Craig WS, Mullen D, Tschopp JF, Dixon D, Pierschbacher MD. Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin aIIbp3 antagonists. J Med Chem 1994; 3: 1-8
    PubMedGoogle Scholar